Pulmonary vascular diseases are usually diagnosed at a late stage when pulmonary arterial pressure and pulmonary vascular resistance are markedly elevated, patients are functionally limited, pathological changes are not fully reversible, and prognosis is bad. This program line builds up a comprehensive clinical database in close cooperation with the Division of Pulmonology and Biobank. This will lead to a better understanding of the long-term disease progression and the recognition of clinically relevant parameters including biomarkers. The program line is also responsible for the planning and performance of "proof of concept trials" evaluating novel therapy concepts developed within the LBI.
- Clinical database
- Early recognition of pulmonary hypertension (PH)
- Non-invasive screening and follow-up of PH
- Standardization of exercise tests used in the management of PH patients